Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 10, 2016, Pages 1168-1175

  Ventetuolo, Corey E ^a,b   Baird, Grayson L ^b   Graham Barr, R ^c   Bluemke, David A ^d   Fritz, Jason S ^e   Hill, Nicholas S ^f   Klinger, James R ^a,b   Lima, Joao A C ^g   Ouyang, Pamela ^g   Palevsky, Harold I ^e   Palmisciano, Amy J ^b   Krishnan, Ipsita ^b   Pinder, Diane ^e   Preston, Ioana R ^f   Roberts, Kari E ^f   Kawut, Steven M ^e  

^a BROWN UNIVERSITY   (United States)

^b Lifespan   (United States)

^c Columbia University ^*  (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DHEA; Estradiol; Pulmonary hypertension; Sex hormones

Indexed keywords

ESTRADIOL; PRASTERONE SULFATE;

AGED; BLOOD; CASE CONTROL STUDY; HUMAN; MALE; MIDDLE AGED; PULMONARY HYPERTENSION; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84987608841     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201509-1785OC     Document Type: Article

References (49)

1. HumbertM, Sitbon O, Chaouat A, BertocchiM, Habib G, Gressin V, Yaïci A, Weitzenblum E, Cordier J-F, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
2. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122:164-172.
3. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, Tighiouart H, Knowles JA, Rabinowitz D, Benza RL, et al.; Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835-842.
4. Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD, Kawut SM. Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J 2014; 43:523-530.
5. Alzoubi A, Toba M, Abe K, O'Neill KD, Rocic P, Fagan KA, McMurtry IF, Oka M. Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2013; 304:H1708-H1718.
6. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA, Justice MJ, Brown MB, Van Demark M, Trulock KM, et al. 17b-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptormediated effects. Am J Respir Crit Care Med 2012; 185:965-980.
7. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, et al. Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation 2012; 126:1087-1098.
8. Mair KM, Yang XD, Long L, White K, Wallace E, Ewart MA, Docherty CK, Morrell NW, MacLean MR. Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2015; 191:693-703.
9. Homma N, Nagaoka T, Karoor V, Imamura M, Taraseviciene-Stewart L, Walker LA, Fagan KA, McMurtry IF, Oka M. Involvement of RhoA/Rho kinase signaling in protection against monocrotalineinduced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am J Physiol Lung Cell Mol Physiol 2008; 295:L71-L78.
10. Mair KM, Wright AF, Duggan N, Rowlands DJ, Hussey MJ, Roberts S, Fullerton J, Nilsen M, Loughlin L, Thomas M, et al. Sex-dependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med 2014; 190:456-467.
11. Tofovic SP. Estrogens and development of pulmonary hypertension: Interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010; 56:696-708.
12. McMurtry IF, Frith CH, Will DH. Cardiopulmonary responses of male and female swine to simulated high altitude. J Appl Physiol 1973; 35: 459-462.
13. Liu J, Wu S, Wei H, Zhou K, Ruan Y, Lai W. Effects of sex hormones and their balance on the proliferation of rat vascular endothelial cells. Horm Res 2002; 58:16-20.
14. Hemnes AR, Maynard KB, Champion HC, Gleaves L, Penner N, West J, Newman JH. Testosterone negatively regulates right ventricular load stress responses in mice. Pulm Circ 2012; 2:352-358.
15. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA. Testosterone supplementation in heart failure: A meta-analysis. Circ Heart Fail 2012; 5:315-321.
16. Rochira V, Guaraldi G. Hypogonadism in the HIV-infected man. Endocrinol Metab Clin North Am 2014; 43:709-730.
17. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellström D, Ohlsson C. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94: 2482-2488.
18. Tivesten A, Mellström D, Jutberger H, Fagerberg B, Lernfelt B, Orwoll E, Karlsson MK, Ljunggren O, Ohlsson C. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol 2007; 50:1070-1076.
19. Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Krishnan I, Lima JAC, Ouyang P, et al. Sex hormones in men with pulmonary arterial hypertension: A case-control study using the Multi-Ethnic Study of Atherosclerosis [abstract]. Am J Respir Crit Care Med 2015; 191:A4093.
20. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and design. Am J Epidemiol 2002; 156: 871-881.
21. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25):D42-D50.
22. Kawut SM, Lima JA, Barr RG, Chahal H, Jain A, Tandri H, Praestgaard A, Bagiella E, Kizer JR, Johnson WC, et al. Sex and race differences in right ventricular structure and function: The Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study. Circulation 2011; 123: 2542-2551.
23. Natori S, Lai S, Finn JP, Gomes AS, Hundley WG, Jerosch-Herold M, Pearson G, Sinha S, Arai A, Lima JA, et al. Cardiovascular function in Multi-Ethnic Study of Atherosclerosis: normal values by age, sex, and ethnicity. AJR Am J Roentgenol 2006; 186(Suppl 2):S357-S365.
24. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995; 41:264-270.
25. Grandits G, Neuhaus J. Using SAS to perform individual matching in design of case control studies. SAS Global Forum 2010, Seattle, WA, Coders' Corner 2010: Paper 061-2010.
26. Austin ED, Hamid R, Hemnes AR, Loyd JE, Blackwell T, Yu C, Phillips Iii JA, Gaddipati R, Gladson S, Gu E, et al. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ 2012; 3:6.
27. Yang X, Long L, Southwood M, Rudarakanchana N, Upton PD, Jeffery TK, Atkinson C, Chen H, Trembath RC, Morrell NW. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005; 96:1053-1063.
28. Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000; 355:979-983.
29. Fessel JP, Chen X, Frump A, Gladson S, Blackwell T, Kang C, Johnson J, Loyd JE, Hemnes A, Austin E, et al. Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension. Pulm Circ 2013; 3:564-577.
30. Bonnet S, Dumas-de-La-Roque E, Bégueret H, Marthan R, Fayon M, Dos Santos P, Savineau JP, Baulieu EE. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 2003; 100:9488-9493.
31. Hampl V, BíbováJ, PovýsilováV, Herget J. Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats. Eur Respir J 2003; 21:862-865.
32. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2011; 301:H1798-H1809.
33. Dumas de La Roque E, Bellance N, Rossignol R, Begueret H, Billaud M, dos Santos P, Ducret T, Marthan R, Dahan D, Ramos-Barbón D, et al. Dehydroepiandrosterone reverses chronic hypoxia/reoxygenationinduced right ventricular dysfunction in rats. Eur Respir J 2012; 40: 1420-1429.
34. Chen H, Lin AS, Li Y, Reiter CEN, VerMR, QuonMJ. Dehydroepiandrosterone stimulates phosphorylation of FoxO1 in vascular endothelial cells via phosphatidylinositol 3-kinase- and protein kinase A-dependent signaling pathways to regulate ET-1 synthesis and secretion. J Biol Chem2008; 283: 29228-29238.
35. Liu D, Dillon JS. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2, 3). J Biol Chem 2002; 277:21379-21388.
36. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
37. Jacobs W, van de Veerdonk MC, Trip P, de Man F, Heymans MW, Marcus JT, Kawut SM, Bogaard HJ, Boonstra A, Vonk Noordegraaf A. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest 2014; 145:1230-1236.
38. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest 2012; 141:210-221.
39. Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, Straub RH. Estrogens and autoimmune diseases. Ann N Y Acad Sci 2006; 1089:538-547.
40. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest 2002; 109:1625-1633.
41. Behrens M, Trejo T, Luthra H, Griffiths M, David CS, Taneja V. Mechanism by which HLA-DR4 regulates sex-bias of arthritis in humanized mice. J Autoimmun 2010; 35:1-9.
42. Ligeiro de Oliveira AP, Peron JP, Santos Franco AL, Golega BA, Vieira RP, Ibanez OC, Ribeiro OG, Cabrera WH, De Franco M, Oliveira-Filho RM, et al. Ovariectomized OVA-sensitized mice display increased frequency of CD4(1)Foxp3(1) T regulatory cells in the periphery. PLoS One 2013; 8:e65674.
43. Fijak M, Schneider E, Klug J, Bhushan S, Hackstein H, Schuler G, Wygrecka M, Gromoll J, Meinhardt A. Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: Evidence for a direct role of testosterone on regulatory T cell expansion. J Immunol 2011; 186:5162-5172.
44. Bobjer J, Katrinaki M, Tsatsanis C, Lundberg Giwercman Y, Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: A nested cross-sectional study. PLoS One 2013; 8:e61466.
45. Tengstrand B, Carlström K, Felländer-Tsai L, Hafström I. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: High correlation between serum estradiol and current degree of inflammation. J Rheumatol 2003; 30: 2338-2343.
46. Joffe HV, Ridker PM, Manson JE, Cook NR, Buring JE, Rexrode KM. Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease. Ann Epidemiol 2006; 16: 105-112.
47. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009; 361:1152-1163.
48. Liao CH, Li HY, Yu HJ, Chiang HS, Lin MS, Hua CH, Ma WY. Low serum sex hormone-binding globulin: Marker of inflammation? Clin Chim Acta 2012; 413:803-807.
49. Arnlöv J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D'Agostino RB Sr, Bhasin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 2006; 145:176-184.